Stefano Sammicheli

Stefano Sammicheli

Auto-generated profile, based on publicly available information

Stefano Sammicheli

Ichnos Glenmark Innovation, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MMMaud Mayoux
Maud Mayoux
ARAndreas Roller
Andreas Roller
VPVesna Pulko
Vesna Pulko
SSStefano Sammicheli
Stefano Sammicheli
SCStanford Chen
Stanford Chen
WXWei Xu
Wei Xu
DCs are critical cellular targets of PD-L1 blockade in cancer treatment.

6 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CGC. Grandclément
C. Grandclément
CEC. Estoppey
C. Estoppey
EDE. Dheilly
E. Dheilly
MPM. Panagopoulou
M. Panagopoulou
TMT. Monney
T. Monney
SSS. Sammicheli
S. Sammicheli
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malignancies. ISB 1442 consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity-induced blocking of proximal CD47 receptors on the same cell while preventing on-target off-tumor binding on healthy cells. The Fc portion of ISB 1442 is engineered to enhance complement dependent cytotoxicity, antibody dependent cell cytotoxicity and antibody dependent cell phagocytosis. ISB 1442 thus represents a CD47-BsAb combining biparatopic targeting of a tumor associated antigen with engineered enhancement of antibody effector function to overcome potential resistance mechanisms that hamper treatment of myeloma with monospecific anti-CD38 antibodies. ISB 1442 is currently in a Phase I clinical trial in relapsed refractory multiple myeloma.

1 April 2013 in Vaccine
Verified
Journal Article
Closed access
ACAlberto Cagigi
Alberto Cagigi
SPSimone Pensieroso
Simone Pensieroso
NRNicolas Ruffin
Nicolas Ruffin
SSStefano Sammicheli
Stefano Sammicheli
RTRigmor Thorstensson
Rigmor Thorstensson
FCFrancesca Chiodi
Francesca Chiodi